DexCom, Inc.
DXCM
$79.28
-$1.49-1.85%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.30B | 4.15B | 4.03B | 3.95B | 3.93B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.30B | 4.15B | 4.03B | 3.95B | 3.93B |
| Cost of Revenue | 1.77B | 1.68B | 1.59B | 1.52B | 1.47B |
| Gross Profit | 2.53B | 2.47B | 2.44B | 2.44B | 2.47B |
| SG&A Expenses | 1.27B | 1.28B | 1.29B | 1.26B | 1.24B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.61B | 3.52B | 3.43B | 3.33B | 3.25B |
| Operating Income | 687.20M | 632.60M | 600.00M | 628.00M | 681.50M |
| Income Before Tax | 784.10M | 730.80M | 709.00M | 743.90M | 806.90M |
| Income Tax Expenses | 212.60M | 195.60M | 132.80M | 63.10M | 140.00M |
| Earnings from Continuing Operations | 571.50 | 535.20 | 576.20 | 680.80 | 666.90 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 571.50M | 535.20M | 576.20M | 680.80M | 666.90M |
| EBIT | 687.20M | 632.60M | 600.00M | 628.00M | 681.50M |
| EBITDA | 923.30M | 857.80M | 817.70M | 840.40M | 886.80M |
| EPS Basic | 1.46 | 1.36 | 1.46 | 1.74 | 1.71 |
| Normalized Basic EPS | 1.25 | 1.16 | 1.13 | 1.19 | 1.30 |
| EPS Diluted | 1.43 | 1.33 | 1.42 | 1.67 | 1.62 |
| Normalized Diluted EPS | 1.20 | 1.11 | 1.08 | 1.12 | 1.20 |
| Average Basic Shares Outstanding | 1.57B | 1.58B | 1.57B | 1.57B | 1.56B |
| Average Diluted Shares Outstanding | 1.63B | 1.64B | 1.65B | 1.66B | 1.68B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |